TGFB1 and myelodysplastic syndrome: In MDS miR‐21 mediates hematopoietic suppression by targeting Smad7, a negative regulator of the TGFβ pathway (Bhagat et al., 2013), while miR‐22 upregulation correlates with poor survival (Song et al., 2013).